Skip to content

Allogenic bone marrow-derived mesenchymal stem cells transplantation in severe cerebral infarction patients: a randomized controlled clinical trail

Allogenic bone marrow-derived mesenchymal stem cells transplantation in severe cerebral infarction patients: a randomized controlled clinical trail

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16008908
Enrollment
Unknown
Registered
2016-07-25
Start date
2016-07-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

intervention group:regular treatment plus intrathecal injection of stem cells
control group:regular treatment

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-75 years old; 2. between 1 to 3 months from stroke onset; 3. met diagnostic criteria of stroke; first onset or previous illness but good recovery (no dysfunction); 4. legacy severe neurologic deficits, but no longer progress, NIHSS scores 15-25; 5. written informed consents were obtained from all subjects.

Exclusion criteria

Exclusion criteria: 1. the specific causes of cerebral infarction(Such as the central nervous system vasculitis, syphilitic cerebrovascular inflammation, blood clotting disorders, etc), cerebral infarction again within 3 months; 2. cerebral infarction complicated with cerebral hemorrhage, subarachnoid hemorrhage and hemorrhagic transformation; 3. severe disturbance of consciousness(Lethargy or coma); 4. cerebral hernia, status epilepticus; 5. critically ill: Vital signs (respiration, blood pressure, blood oxygen, heart rate, etc.) are not stable and/or multiple organ dysfunction; 6. cerebral infarction complicated with infections, infectious disease, myocardial infarction (within 3 months), chronic renal insufficiency, liver function abnormalities, diabetes(poor blood glucose control) or with severe nerve vascular complications, autoimmune diseases; 7. other neurological disorders, dementia, or mental illness affecting the compliance and evaluation; 8. cancer patients; 9. abnormal blood system: HGB<90g/L, WBC<4.0×10^9/L, PLT<100×10^9/L, or blood coagulation disorders; 10. allergic constitution; 11. pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
mRS scale;

Secondary

MeasureTime frame
NIHSS score;infarct volume;neurologic function score;mortality within 13 months after treatment;cerebralspinal fluid biomarkers;

Countries

China

Contacts

Public ContactYidong Wang

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

wydys@126.com+86 020-34070569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 6, 2026